Osimertinib (osi) after definitive chemoradiotherapy (CRT) in patients (pts) with unresectable stage (stg) III epidermal growth factor receptor-mutated (EGFRm) NSCLC: Primary results of the phase 3 LAURA study.

Autor: Ramalingam, Suresh S., Kato, Terufumi, Dong, Xiaorong, Ahn, Myung-Ju, Quang, Le-Van, Soparattanapaisarn, Nopadol, Inoue, Takako, Wang, Chih-Liang, Huang, Meijuan, Yang, James Chih-Hsin, Cobo, Manuel, Özgüroğlu, Mustafa, Casarini, Ignacio, Khiem, Dang-Van, Sriuranpong, Virote, Cronemberger, Eduardo, Huang, Xiangning, van der Gronde, Toon, Ghiorghiu, Dana C., Lu, Shun
Zdroj: Journal of Clinical Oncology; 2024 Supplement 17, Vol. 42, pLBA4-LBA4, 83p
Databáze: Supplemental Index